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A b s t r a c t
Background: Serglycin plays a key role in the inflammatory status however the relationship between coronary artery disease 
(CAD) and serglycin is still unknown. 
Aim: In this study, we aimed to investigate association of serglycin levels with CAD severity in patients with stable angina 
pectoris (SAP).
Methods: In total, 100 SAP patients diagnosed by coronary angiography and clinical manifestations, and 100 control subjects 
matched for age and sex were enrolled in this case-control study. Plasma levels of serglycin, high-sensitivity C-reactive protein 
(hsCRP), lipid profiles, and clinical parameters were assayed for all participants. The severity of coronary lesions was evaluated 
based on the SYNTAX score (SS) assessed by coronary angiography.
Results: Positively correlated with the SS (r = 0.564, p < 0.001), the plasma serglycin level in the SAP group was higher 
than that in the control group (11.17 ± 1.82 vs. 19.28 ± 1.88 ng/mL, p < 0.001). The plasma serglycin level was an inde-
pendent predictor for both SAP (odds ratio [OR] 1.037, 95% confidence interval [CI] 1.020–1.054, p < 0.001) and a high 
SS (OR = 1.087, 95% CI 1.051–1.124, p < 0.001) in a multivariate logistic regression model. In the receiver operating  
characteristic curve analysis, the plasma serglycin level was found to have a better predictive value for a high SS (area under the 
curve [AUC] 0.858, 95% CI 0.788–0.929, p < 0.001) compared with hsCRP (AUC 0.665, 95% CI 0.557–0.773, p = 0.006; 
Z = 2.94, p < 0.001), with an optimal cut-off value of 17.25 ng/mL (sensitivity 94.3%, specificity 68.2%).
Conclusions: Plasma serglycin levels correlate with both the presence and severity of coronary stenosis in patients with SAP, 
suggesting that it could be a potential predictive marker of severe stenosis in SAP patients.
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INTRODUCTION
Recent research has shown that inflammation plays a key role 
in coronary artery disease (CAD) and other manifestations of 
atherosclerosis. Immune cells dominate early atherosclerotic 
lesions, their effector molecules accelerate progression of 
the lesions, and activation of inflammation can elicit acute 
coronary syndromes. Atherosclerosis, the main cause of CAD, 
is an inflammatory disease in which immune mechanisms 
interact with metabolic risk factors to initiate, propagate, and 
activate lesions in the arterial tree [1]. Stable angina pectoris 
(SAP) is one of the most common subtypes of CAD, affecting 
approximately 54 million patients worldwide. An individual’s 
prognosis can vary greatly, from chronic recurrent angina 
pectoris to acute myocardial infarction. Early and accurate 
identification of SAP patients with high risk is of great clinical 
value [2]. An increasing number of inflammatory markers 
and acute phase proteins have been tested in CAD, and their 
plasma levels have been confirmed to be correlated with 
different clinical characteristics and the prognosis of these 
patients [3]. However, there is a lack of clinically useful, highly 
specific biomarkers for SAP to guide treatment decisions for 
SAP patients. 
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Serglycin is associated with intracellular proteoglycan 
and haematopoietic cells. Prior studies showed that some 
non-haematopoietic cell types also synthesise serglycin. In-
flammatory cells synthesise serglycin then store it in granules 
to react with mediators, for instance, cytokines, chemokines, 
growth factors, and proteases [4, 5]. Serglycin can also par-
ticipate in the formation of atheromatous lesions and athero-
sclerosis. It has been shown that serglycin is up-regulated by 
lipopolysaccharides in macrophages, tumour necrosis factor 
(TNF) in endothelial cells, and interleukin 1-b in smooth 
muscle cells [6]. Because of these findings, serglycin plays 
a role in the inflammatory status and in the development of 
vascular diseases, and we hypothesise that serglycin might be 
involved in CAD. Therefore, we aim to investigate the asso-
ciation between serglycin levels and CAD severity in patients 
with SAP. To the best of our knowledge, this is the first study 
of its kind in the literature.
METHODS
Study population
We consecutively recruited 100 CAD patients with SAP at 
Sivas Numune Hospital from July 2016 to March 2017 for 
this study. SAP was defined as chest pain typical for cardiac 
ischaemia on exertion or emotional stress that is relieved by 
rest or nitrates. The pattern of chest pain did not change within 
at least one month. All patients had undergone coronary 
angiography and had angiographically documented narrow-
ing of at least 50% of the luminal diameter of an epicardial 
coronary artery. Subjects with acute myocardial infarction, 
systolic and diastolic heart failure, cardiomyopathies, and 
valvular disease were excluded. Also, in the same date range, 
a total of 100 age- and sex-matched controls without CAD 
were enrolled. They were found to be free of CAD based 
on no history of angina and other heart diseases as well as 
a normal electrocardiogram (ECG), and exercise ECG stress 
testing. The exclusion criteria for both groups were as fol-
lows: acute or chronic infection, definite inflammatory and 
immune-associated diseases, bleeding, surgery or trauma 
within 12 weeks prior to admission, liver or renal dysfunc-
tion, and malignancy. Patients were also excluded if they had 
been taking statins or any anti-inflammatory drugs. Patients 
received acetylsalicylic acid (ASA) before the blood samples 
were taken, but the dose of ASA was 100 mg/day (low dose) 
so the anti-inflammatory effect was small. The study protocol 
complied with the Declaration of Helsinki. All the participants 
gave written, informed consent.
The participants were diagnosed with arterial hyperten-
sion if their systolic blood pressure was ≥ 140 mmHg and/or 
their diastolic blood pressure was ≥ 90 mmHg. Hyperten-
sion was also diagnosed if a patient self-reported a previous 
diagnosis of this disease established by a physician or if any 
anti-hypertensive treatment was being taken at admission. 
Diabetes mellitus was diagnosed according to the American 
Diabetes Association, which include a fasting plasma glucose 
level ≥ 126 mg/dL, a 2-h post-load glucose level ≥ 200 mg/dL, 
self-report of a physician’s diagnosis, and any hypoglycaemic 
medication taken at admission. Smokers were defined as those 
who regularly smoked five cigarettes or more per day, and if 
patients had stopped smoking for more than 10 years preced-
ing the disease onset, they were classified as non-smokers. In 
addition, body mass index (BMI) was calculated as weight 
(kg)/height2 (m2). The definitions of systolic and diastolic heart 
failure were determined according to the 2016 European 
Society of Cardiology guidelines.
Coronary angiography
Selective coronary angiography was performed using a stand-
ard Judkins technique. CAD was defined as the presence 
of obstructive stenosis in any of the main coronary arteries, 
including the left main coronary artery, left anterior descending 
artery, left circumflex coronary artery, right coronary artery, 
and any of the main branches of the vascular system of more 
than 50% of the lumen diameter. The severity of coronary 
lesions was assessed by the SYNTAX score (SS), which was 
calculated for all patients by two experienced interventional 
cardiologists who were unaware of the patients’ clinical or 
laboratory results. SS was determined for all coronary lesions 
with > 50% diameter stenosis in a vessel > 1.5 mm based 
on a SS calculator 2.1 (www.syntaxscore.com). SAP patients 
were divided into three subgroups: high SS (> 32; 32 pa-
tients), intermediate SS (22 < n ≤ 32; 28 patients), and low 
SS (≤ 22; 40 patients).
Laboratory tests
Blood samples from the patients after a fasting period of 12 h 
were collected into plain tubes, serum was separated after 
centrifugation at 4000 g for 10 min, and stored at –80°C until 
analysis. We obtained all the blood samples after coronary 
angiography in the SAP group. Complete blood count and 
differentials were measured from the peripheral venous 
blood samples obtained at admission. An automatised 
analyser was used to measure high-sensitivity C-reactive 
protein (hsCRP), total cholesterol, triglyceride, creatinine, 
low-density lipoprotein cholesterol (LDL-C), and high-density 
lipoprotein cholesterol (HDL-C). Serglycin levels in plasma 
were determined by a previously described enzyme-linked 
immunosorbent assay [7].
Statistical analysis
All statistical analyses were performed using the SPSS 
20.0 software package (SPSS Inc., Chicago, IL, USA). The 
Kolmogorov-Smirnov test was used to determine data distri-
bution patterns. Continuous variables are presented as the 
mean ± standard deviation or median with the 25th and 75th 
percentile, as appropriate. Variables with a skewed distribution 
were log-transformed for further statistical testing. Differences 
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between groups were compared using the t-test or one-way 
ANOVA. Categorical variables are expressed as frequencies or 
percentages, and differences were compared with the c2 test 
or Fisher’s exact test. 
We calculated that enrolment of 100 patients with SAP 
in the study group and 100 individuals in the control group 
would provide a 90% power to demonstrate a significant dif-
ference (p = 0.05) in serglycin levels between patients with 
SAP and control subjects. Pearson and Spearman correlation 
coefficients were used to evaluate the correlations between 
serglycin plasma concentration and other variables, when ap-
propriate. Subsequently, multiple linear regression analysis was 
performed to investigate a set of independent risk factors as-
sociated with the plasma serglycin level. Spearman correlation 
analysis was also used to determine the correlations between 
plasma serglycin levels and SSs in SAP patients. The predictive 
values of different clinical variables for the SAP risk and high 
SS (> 32) were found using the univariate and multivariate 
logistic regression models. Receiver operating characteristic 
(ROC) curves were generated to assess the diagnostic value of 
plasma serglycin for SAP and high SS. The maximum Youden 
index was used to determine the optimal cut-off values. The 
diagnostic values of plasma serglycin and hsCRP were com-
pared using the Z test. A value of p < 0.05 was considered 
to indicate a statistically significant difference.
RESULTS
Baseline clinical characteristics  
of the study population
To investigate the relationship between plasma serglycin levels 
and SAP, 200 subjects were enrolled in the present study, in-
cluding 100 SAP patients and 100 non-CAD controls. Because 
the inflammation-modulating capacity of statins has been 
confirmed, patients treated with statins were excluded from 
our study. Thus, data regarding the effects of statin use are not 
presented. The baseline clinical characteristics and biochemi-
cal parameters of the study population are summarised in 
Table 1. Age, sex, BMI, smoking status, and the presence of 
diabetes showed no significant difference between the SAP 
group and the control group. When we classified the SAP pa-
tients according to the severity of symptoms (class 1–4 angina, 
according to European Society of Cardiology stable coronary 
Table 1. Baseline characteristics of the study population
Variables Control group (n = 100) SAP group (n = 100) p
Demographic and clinical data:
Men 77 74 0.542
Age [years] 51.62 ± 8.35 52.01 ± 8.75 0.264
Body mass index [kg/m2] 24.92 ± 3.37 25.36 ± 3.74 0.260
Diabetes 18 22 0.225
Arterial hypertension 55 64 0.071
Smoking 53 51 0.771
Biochemical parameters:
Total cholesterol [mg/dL] 251 ± 30.1 269 ± 28.8 0.639
Triglyceride [mg/dL] 188 ± 29.9 200 ± 18.8 0.415
HDL-C [mg/dL] 48 ± 8.4 32 ± 7.7 0.005
LDL-C [mg/dL] 145 ± 20.1 184 ± 31.1 0.004
NT-proBNP [pg/mL] 98 ± 8.4 101 ± 7.7 0.124
hsCRP [mg/L] 1.08 (0.62–1.76) 2.02 (1.07–3.38) < 0.001
Serglycin [ng/mL] 11.17 ± 1.82 19.28 ± 1.88 < 0.001
Medications:
Statins 0 0 0
Aspirin 11 15 0.296
Calcium channel blocker 20 20 0.727
ACEI/ARB 13 20 0.254
b-blocker 27 37 0.123
Data are shown as mean ± standard deviation or number. ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin-receptor blocker; 
HDL-C — high-density lipoprotein cholesterol; hsCRP — high-sensitivity C-reactive protein, presented as median with 25th and 75th percentiles;  
LDL-C — low-density lipoprotein cholesterol; NT-proBNP — N-terminal pro B-type natriuretic peptide; SAP — stable angina pectoris
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artery disease guideline), we could not find any association 
between CAD severity and symptom severity (p = 0.12). As 
expected, patients in the SAP group had significantly higher 
mean levels of plasma hsCRP, serglycin, and LDL-C and a lower 
mean HDL-C level compared with the control group.
Plasma serglycin concentration assessment
The plasma serglycin concentrations for all subjects ranged 
from 9.15 to 26.10 ng/mL with a median of 14.93 ng/mL. In 
the total population studied, the plasma serglycin concentra-
tion was positively correlated with age, smoking status, and 
the plasma hsCRP level, and negatively correlated with the 
plasma HDL-C level (Table 2). In covariance analysis, the 
plasma serglycin concentration adjusted for these possible 
confounding factors was still higher in the SAP group than that 
in the controls (11.17 ± 1.82 ng/mL vs. 19.28 ± 1.88 ng/mL, 
p < 0.001).
Correlations between plasma serglycin  
concentration and stable angina pectoris
To confirm the predictive value of an increased plasma sergly-
cin level for SAP, univariate and multivariate logistic regression 
analyses were performed. As shown in Table 3, plasma levels 
of LDL-C, hsCRP and serglycin were found to be independ-
ent predictors of SAP (LDL-C: odds ratio [OR] 1.724, 95% 
confidence interval [CI] 1.100–2.702, p = 0.017; hsCRP: 
OR 2.908, 95% CI 1.402–6.033, p = 0.004; serglycin: OR 
1.037, 95% CI 1.020–1.054, p < 0.001). To test the diagnostic 
value of plasma serglycin concentration for SAP, ROC curves 
were established. As shown in Figure 1A, the value of plasma 
serglycin  and hsCRP levels in distinguishing patients with SAP 
from controls was comparable (for serglycin: area under the 
curve [AUC] 0.721, 95% CI 0.655–0.788, p < 0.001, and 
for hsCRP: AUC 0.698, 95% CI 0.628–0.768, p < 0.001, 
Z = 0.46, p = 0.105). The plasma serglycin concentration was 
of certain value in predicting SAP with a sensitivity of 63.4% 
and a specificity of 67.8%. The best cut-off value calculated 
using the Youden index was 16.72 ng/mL.
Correlations between plasma serglycin  
concentration and SYNTAX score
The SYNTAX score was used to assess the severity of coronary 
atherosclerotic lesions. SAP patients were divided into three 
subgroups according to angiographic findings. The baseline 
characteristics of these subgroups are presented in Table 4. 
Patients with a high SS had higher plasma serglycin levels, 
while those with a low or intermediate SS had the lowest serg-
lycin levels (low SS subgroup ≤ 22; 13.17 ± 2.83 ng/mL, inter-
mediate SS subgroup 22 < n ≤ 32; 14.22 ± 2.45 ng/mL, high 
SS subgroup > 32: 20.68 ± 3.98 ng/mL). To further investigate 
the association between plasma serglycin concentrations and 
coronary severity, Spearman analysis was performed. As shown 
in Figure 2, there was a significant positive correlation between 
plasma serglycin levels and SS in patients with SAP (n = 100, 
r = 0.564, p < 0.001). Additionally, we performed univari-
ate analysis between the SAP patients with high SS (> 32) 
Table 2. Correlations between the plasma serglycin concentration and other variables
Variables Univariate analysis Multivariate analysis
r p b coefficient B (95% CI) p
Men 0.068 0.317 – – –
Age 0.182 0.007 0.493 0.171–0.815 0.003
Body mass index 0.669 0.504 – – –
Diabetes 0.049 0.469 – – –
Arterial hypertension 0.245 0.111 1.324 −4.391–7.038 0.648
Smoking 0.153 0.023 6.238 0.721−11.756 0.027
Total cholesterol −0.028 0.690 – – –
Triglycerides −0.108 0.114 – – –
HDL-C −0.184 0.006 −9.701 −18.953– −0.449 0.040
LDL-C 0.121 0.072 – – –
hsCRP 0.297 < 0.001 10.691 5.021–16.362 < 0.001
Aspirin 0.109 0.105 – – –
Calcium channel blocker 0.008 0.902 – – –
ACEI/ARB 0.039 0.569 – – –
b-blocker 0.129 0.056 – – –
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin-receptor blocker; CI — confidence interval; HDL-C — high-density lipoprotein 
cholesterol; hsCRP — high-sensitivity C-reactive protein; LDL-C — low-density lipoprotein cholesterol; OR — odds ratio
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and those with low or intermediate SS (≤ 32). Patients with 
high SS (> 32) were more often older and had significantly 
elevated plasma serglycin and hsCRP levels. Moreover, the 
multivariate logistic regression analysis showed that only the 
plasma serglycin level was shown as an independent predictor 
of high SS in SAP patients (OR 1.087, 95% CI 1.051–1.124, 
p < 0.001), which suggests a more severe atherosclerotic le-
sion. Finally, the ROC curve analysis (Fig. 1B) showed a moder-
ate diagnostic value of plasma serglycin levels for identifying 
SAP patients with high SS from those with low or intermediate 
SS (AUC 0.858, 95% CI 0.788–0.929, p < 0.001), and it was 
better than that of plasma hsCRP levels (AUC 0.665, 95% CI 
0.557–0.773, p = 0.006, Z = 2.9363, p < 0.001). Addition-
ally, we found that a plasma serglycin level of 17.25 ng/mL 
was an effective cut-off point for differentiating SAP patients 
with severe atherosclerotic lesions from those without, with 
a sensitivity of 94.3% and a specificity of 68.2%.
DISCUSSION
Our study demonstrated that plasma serglycin levels were 
significantly higher in patients with SAP than in controls. An 
elevated plasma serglycin level was found to be an independ-
ent risk factor for both the presence of SAP and high SS. The 
ROC curve analysis indicated that plasma serglycin level 
could be a potential marker of the presence and severity of 
SAP; in particular, a plasma serglycin level of 17.25 ng/mL or 
higher identified SAP patients with high SSs with a sensitivity 
of 94.3% and a specificity of 68.2%. All these findings suggest 
that plasma serglycin levels could serve as a valuable predic-
tor in the screening of SAP patients for more severe coronary 
stenosis, and these patients would greatly benefit from further 
Table 3. Univariate and multivariate logistic regression  
analyses of risk factors and laboratory parameters to  
identify independent predictors of stable angina pectoris 
Variables OR 95% CI P
Univariate analysis
Men 1.201 0.678–2.130 0.530
Age 0.978 0.948–1.009 0.164
BMI 1.036 0.961–1.117 0.356
Diabetes 1.597 0.807–3.163 0.179
Arterial hypertension 2.787 1.595–4.870 < 0.001
Smoking 1.113 0.655–1.891 0.693
Total cholesterol 1.089 0.771–1.540 0.628
Triglyceride 1.073 0.817–1.408 0.613
HDL-C 0.256 0.097–0.677 0.006
LDL-C 1.742 1.161–2.615 0.007
hsCRP 4.395 2.194–8.806 < 0.001
Serglycin 1.044 1.028–1.060 < 0.001
Aspirin 1.658 0.725–3.793 0.231
Calcium channel blocker 1.181 0.595–2.343 0.635
ACEI/ARB 1.946 0.915–4.142 0.084
b-blocker 1.889 1.049–3.404 0.034
Multivariate analysis
LDL-C 1.724 1.100–2.702 0.017
hsCRP 2.908 1.402–6.033 0.004
Serglycin 1.037 1.020–1.054 < 0.001
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin-
-receptor blocker; BMI — body mass index; CI — confidence interval; 
HDL-C — high-density lipoprotein cholesterol; hsCRP — high-sensitivity 
C-reactive protein; LDL-C — low-density lipoprotein cholesterol; OR — 
odds ratio
Figure 1. Receiver operating characteristic (ROC) curve analyses of the predictive ability of plasma serglycin levels; A. ROC curve 
analysis for stable angina pectoris; B. ROC curve analysis for a high SYNTAX score (≥ 32) identification; AUC — area under the 
curve; CI — confidence interval; hsCRP — high-sensitivity C-reactive protein
BA
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examination and treatment, such as percutaneous coronary 
intervention and stenting.
Serglycin is a dominant intracellular proteoglycan ex-
pressed by immune cells, where it interacts with many inflam-
matory mediators, such as proteases, chemokines, cytokines, 
and growth factors [4, 5]. In a recent study serglycin was 
found to be among the most abundantly expressed proteins in 
adiposities of epicardial adipose tissue in patients with CAD. 
It was also demonstrated that TNF-a induces expression and 
secretion of serglycin in adipocytes. These observations suggest 
that serglycin and TNF-a contribute to the development and 
progression of CAD through cross-talk between macrophages 
and adiposities [8]. Circulating serglycin might also participate 
to atheromatous lesion formation [9, 10]. The biosynthesis 
of serglycin is up-regulated by lipopolysaccharides in mac-
rophages [9, 10], TNF in endothelial cells, and interleukin 1b 
in smooth muscle cells [6]. On the other hand, Kundi et al. 
[11] found that serglycin was significantly higher in patients 
with coronary artery ectasia.
Coronary artery disease is an inflammation-mediated 
atherosclerotic disease [12]. Multiple inflammatory cells and 
mediators have been reported to help sustain and amplify 
pro-inflammatory signals, leading to the onset and development 
of atherosclerosis. Therefore, we supposed that the elevation 
of plasma serglycin levels in SAP patients could be the result 
of the chronic inflammatory status. This was supported by the 
positive correlation between plasma hsCRP and serglycin levels 
observed in the current study population. In addition to inflam-
mation, plasma serglycin levels were also found to be positively 
correlated with age and smoking status, and negatively cor-
related with HDL-C plasma levels. Old age, smoking, and low 
Table 4. Baseline characteristics based on SYNTAX score (SS) in stable angina pectoris (SAP) group
Variables Low SS  
(≤ 22, n = 40)
Intermediate SS 
(22 < n ≤ 32, n = 28)
High SS  
(> 32, n = 32)
p
Men 25 18 20 0.129
Age [years] 52.21 ± 7.36 53.23 ± 8.84 55.69 ± 9.53 0.071
Body mass index [kg/m2] 25.48 ± 3.55 25.88 ± 4.12 26.54 ± 3.33 0.214
Diabetes 13 9 10 0.699
Arterial hypertension 21 15 16 0.893
Smoking 22 16 18 0.684
Total cholesterol [mg/dL] 251 ± 30.1 249 ± 24.1 259 ± 30.4 0.692
Triglyceride [mg/dL] 205 ± 11.7 210 ± 9.7 215 ± 11.1 0.612
HDL-C [mg/dL] 35 ± 5.1 34 ± 4.7 32 ± 3.3 0.640
LDL-C [mg/dL] 177 ± 23.1 171 ± 19.4 188 ± 14.7 0.238
hsCRP [mg/L] 1.83 (0.96–3.62) 1.91 (0.98–3.84) 2.66 (1.67–3.55) 0.013
Serglycin [ng/mL] 13.17 ± 2.83 14.22 ± 2.45 20.68 ± 3.98 < 0.001
Statins 0 0 0 0
Aspirin 9 5 6 0.605
Calcium channel blocker 10 7 8 0.860
ACEI/ARB 9 6 7 0.948
b-blocker 17 11 13 0.619
Data are shown as mean ± standard deviation or number. ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin-receptor blocker; 
HDL-C — high-density lipoprotein cholesterol; hsCRP — high-sensitivity C-reactive protein, presented as the median with 25th and 75th percentiles; 
LDL-C — low-density lipoprotein cholesterol
Figure 2. Correlation between the plasma serglycin level and 
the SYNTAX score in the stable angina pectoris (SAP) patients.  
There was a significantly positive correlation between the 
plasma serglycin level and the SYNTAX score in SAP patients 
(r = 0.564, p < 0.001)
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plasma HDL-C level were all related to high plasma serglycin 
levels, and after adjusting for these possible confounders, the 
plasma serglycin level was still associated with SAP. The ROC 
curve analysis further demonstrated that plasma serglycin level 
was an independent predictor of SAP. The SS has been used to 
evaluate the severity of CAD. In our study, a positive correla-
tion between plasma serglycin levels and SS was confirmed in 
patients with SAP. After adjusting for other risk factors, plasma 
serglycin levels were still related to a high SS, indicating that the 
plasma serglycin concentration is an independent risk factor for 
the severity of SAP. In addition, the ROC curve analysis showed 
that plasma serglycin levels could effectively differentiate SAP 
patients with severe coronary stenosis from those with low or 
intermediate SS.
Serglycin-deficient mice have been found to have im-
paired haemostasis due to a defective thrombosis response 
[13]. It may affect atherosclerosis and the progression of 
CAD through its effect on growth related oncogene a 
(GRO-a) [14]. It has been suggested that the absence of 
serglycin-delivered platelet factor 4 (PF4) could prevent 
atherosclerotic plaque formation because PF4 is involved 
in atherosclerosis [15–17]. All these findings support the 
significant association between plasma serglycin levels and SS 
observed in our study. As a well-known acute phase protein 
in cardiovascular diseases, hsCRP has been confirmed to 
be of a diagnostic value in CAD and to be associated with 
coronary angiographic severity [18]. Our data showed that 
plasma serglycin levels had a similar diagnostic value to that 
of hsCRP levels for SAP. However, the plasma serglycin level 
was more powerful than the hsCRP level for identifying SAP 
patients with a higher SS. Interestingly, plasma serglycin levels 
were better at distinguishing high-SS patients from low- or 
intermediate-SS patients than at distinguishing SAP patients 
from controls. This suggests that measurement of plasma 
serglycin has a greater value for recognising severe coronary 
stenosis in patients with suspected CAD in clinical practice. 
Because there is a need to reduce healthcare costs and the 
risk of cardiovascular events in SAP patients with severe 
coronary stenosis, plasma serglycin levels might be a useful 
screening tool for clinicians. Therefore, SAP patients with sig-
nificantly increased plasma serglycin levels are more inclined 
to receive further evaluation by coronary angiography. In our 
study, the severity of coronary stenosis was only evaluated 
by SS. The association of plaque vulnerability and serglycin 
requires further study with intravascular ultrasound and opti-
cal coherence tomography. Because of the strong correlation 
between serglycin levels and SS, future studies should evalu-
ate plasma serglycin levels in asymptomatic CAD patients. 
There are several limitations to our study. First, our sample 
size was small, and our subjects were obtained from a single 
centre. The diagnostic value of plasma serglycin level needs 
to be further evaluated in a large study population with stand-
ardised diagnostic tests. Second, cardiovascular events were 
not analysed in this study due to its cross-sectional design, 
and the prognostic value of plasma serglycin levels must be 
assessed during  follow-up. On the other hand, we could not 
completely exclude CAD because no coronary angiography 
was performed in control subjects. The other limitation was 
analysing only one inflammatory marker (hs-CRP) to compare 
with serglycin.
In conclusion, our study demonstrated a significantly 
higher plasma serglycin level in patients with SAP compared 
to controls. Plasma serglycin levels were an independent risk 
factor of SAP and higher SS. Plasma serglycin concentrations 
could be measured in SAP patients to predict the severity of 
coronary lesions.
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